Sign In
Buy KOD
$37.05
+0.420 (+1.15%)
At Close: Jun 23, 2026
Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage
12:09pm, Tuesday, 16'th Jun 2026
Kodiak Sciences (KOD) is transitioning from past clinical disappointments to a maturing retina platform with multiple near-term catalysts. Recent GLOW2 Phase 3 success for Zenkuda in diabetic retinopa
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know
07:44pm, Tuesday, 09'th Jun 2026
This clinical-stage biotech focused on retinal therapies reported a notable insider sale amid a year of exceptional stock performance.
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know
12:07pm, Thursday, 04'th Jun 2026
KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
06:09pm, Thursday, 28'th May 2026
PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transf
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
03:57pm, Sunday, 17'th May 2026
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus
01:41pm, Friday, 08'th May 2026
KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
04:00pm, Thursday, 07'th May 2026
PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.
Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supp
Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?
12:31pm, Thursday, 30'th Apr 2026
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus
01:46pm, Wednesday, 01'st Apr 2026
KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
04:45pm, Tuesday, 31'st Mar 2026
PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended Decembe
Kodiak Sciences: Road To $120
10:00am, Monday, 30'th Mar 2026
Kodiak Sciences' stock (NASDAQ: KOD) experienced a substantial 62% surge last week, elevating the stock to $37 and increasing its market capitalization to $2.3 billion. This impressive momentum was fu
Kodiak Sciences (NASDAQ:KOD) Reaches New 52-Week High – Time to Buy?
04:23am, Saturday, 28'th Mar 2026
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) shares hit a new 52-week high during trading on Thursday. The company traded as high as $36.84 and last traded at $36.0160, with a volume of 307524
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate
01:11pm, Friday, 27'th Mar 2026
Kodiak Sciences rallies 75% as phase III GLOW2 data show Zenkuda's strong efficacy, safety and risk reduction in diabetic retinopathy patients.
Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?
10:40am, Friday, 27'th Mar 2026
Investors appear to be responding to both the strength of the data and the possibility of a faster path toward a biologics license application, or BLA. Here's what investors need to know.
